<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03679182</url>
  </required_header>
  <id_info>
    <org_study_id>HE591547</org_study_id>
    <nct_id>NCT03679182</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care</brief_title>
  <official_title>A Pilot Study on Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Khon Kaen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Khon Kaen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oral olanzapine showed superior antiemetic efficacy to metoclopramide as rescue treatment to
      control breakthrough emesis induced by chemotherapy. This study aims to evaluate safety and
      efficacy of olanzapine for nausea and vomiting in advanced cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a pilot study; open-label prospective clinical trial. Oral olanzapine 5 mg
      tablet will be given to patients who fail two standard treatment medications for nausea and
      vomiting within 30 minutes after the first vomiting episode. Other doses of olanzapine will
      be given at 12, 24, and 36 hours following the first dose concurrently with standard regimen.

      Patients with emesis will be followed up after receiving olanzapine every 12 hour for 48
      hours. We will record the frequency of vomiting, nausea, and retching.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Emesis control</measure>
    <time_frame>48 hours</time_frame>
    <description>Percentage of patients without emesis</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <condition>End Stage Cancer</condition>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olanzapine 5 mg at 0, 12, 24 and 36 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Olanzapine 5 mg Tab at 0, 12, 24, and 36 hours</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <other_name>olanzapine 5 mg Tab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-65 years.

          2. Diagnosis of advanced malignancy.

          3. Failed two standard medications for nausea/vomiting (after 6 hours from last dose).

          4. Adequate organ function, including the following:

               1. Hepatic: bilirubin ≤1.5 times the upper limit of normal (x ULN); aspartate
                  aminotransferase (AST), and alanine aminotransferase (ALT) ≤3.0 x ULN (AST, and
                  ALT ≤5 x ULN is acceptable if liver has tumor involvement), alkaline phosphatase
                  (AP) ≤5.0 x ULN.

               2. Renal: calculated creatinine clearance (CrCl) ≥30 mL/min based on the original
                  weight based Cockcroft and Gault formula.

          5. Expected life expectancy &gt; 1 month.

          6. Patients must be able to read Thai.

          7. Patients must sign an informed consent document.

        Exclusion Criteria:

          1. Patients with history of abdominal radiotherapy.

          2. Patients who receive chemotherapy within 1 week.

          3. Patients who take fluoxetine.

          4. Patients with heart failure or myocardial infarction in the past 6 months.

          5. Patients with QTc prolongation from baseline ECG.

          6. Known hypersensitivity to olanzapine.

          7. Patients who are unwilling to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Attakorn Raksasataya, MD</last_name>
    <role>Study Director</role>
    <affiliation>Khon Kaen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jarin Chindaprasirt, MD</last_name>
    <phone>+66846831097</phone>
    <email>jarich@kku.ac.th</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jarin Chindaprasirt</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaruda Sringam, Master</last_name>
      <phone>6643366592</phone>
      <email>talnurse8@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jarin Chindaprasirt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Attakorn Raksasataya, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suthan Chanthawong, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 19, 2018</study_first_submitted>
  <study_first_submitted_qc>September 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2018</study_first_posted>
  <last_update_submitted>September 19, 2018</last_update_submitted>
  <last_update_submitted_qc>September 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Khon Kaen University</investigator_affiliation>
    <investigator_full_name>Jarin Chindaprasirt</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

